CPC A61K 39/145 (2013.01) [A61K 39/12 (2013.01); A61K 39/155 (2013.01); C07K 14/005 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61K 2039/53 (2013.01); C12N 2710/10343 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01); C12N 2800/22 (2013.01); C12N 2840/20 (2013.01)] | 16 Claims |
1. A pharmaceutical composition comprising an adenovirus vector and a pharmaceutically acceptable excipient wherein the adenovirus vector comprises:
(a) a first polynucleotide encoding at least one protein that induces a T cell response directed to a respiratory syncytial virus (RSV) protein, wherein the at least one protein that induces a T cell response is a non-structural or internal protein of RSV that is protein M2, wherein the protein comprises the amino acid sequence of SEQ ID NO: 5;
(b) a second polynucleotide encoding at least one protein, wherein the at least one protein is a fusion protein F surface protein of RSV, which induces an anti-pathogenic B cell response, wherein the protein comprises the amino acid sequence of SEQ ID NO: 1 or 2; and
(c) a third polynucleotide encoding at least one protein, which is a non-structural and internal protein of RSV that is protein N, which induces a T cell response, wherein the protein comprises the amino acid sequence of SEQ ID NO: 3 or 4, wherein the first, the second, and the third polynucleotides are located on the same adenovirus vector.
|